Neumora Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -5,000 | |||
EBITDA | -55,985 | -54,021 | -70,779 | -62,765 |
EBIT | -56,008 | -54,040 | -70,936 | -62,922 |
Net Income | -56,755 | -52,731 | -67,992 | -58,819 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -46,649 | -52,404 | -59,448 | -50,340 |
Cash | 129,071 | 124,523 | 126,860 | 142,148 |
Basic Shares | 161,838 | 161,691 | 161,451 | 160,984 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -668 | -2,697 | -1,551 | |
EBITDA | -262,833 | -187,526 | -135,276 | -236,785 |
EBIT | -263,464 | -188,194 | -135,870 | -237,323 |
Net Income | -243,787 | -235,925 | -130,904 | -237,312 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -182,936 | -163,395 | -115,407 | -76,237 |
Cash | 142,148 | 374,038 | 240,943 | 409,247 |
Basic Shares | 159,377 | 158,832 | 151,949 | 151,949 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$0.35 |
2025-06-30 | -$0.33 |
2025-03-31 | -$0.42 |
2024-12-31 | -$0.37 |
